SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Juno™ Targeted DNA Sequencing Library Preparation System, the industry’s most scalable automated library preparation solution for medium-to-high-throughput next-generation sequencing (NGS). Bringing together the proven Fluidigm® Juno microfluidic automation platform with the benefits of multiplexed target amplification, laboratories can accurately sequence more samples faster and more affordably than ever before.
NGS has been instrumental in advancing the understanding of human health and disease. With these advancements, more samples are being sequenced around the world, driving the need for workflow improvements and greater cost efficiencies. Optimized for use with Illumina sequencers, the Juno Targeted DNA Sequencing Library Preparation System redefines the library preparation workflow from extracted DNA to NGS-ready amplicon libraries.
Supporting a range of panel designs from targeted multiplexed panels covering a few user‑defined genes to more comprehensive panels of up to 4,800 amplicons from hundreds of genes, the system can help laboratories achieve new sequencing efficiencies with consistent performance. With the additional capacity to easily scale up to thousands of samples per week and the flexibility to add new markers over time, laboratories can also be better-positioned to meet the demands of NGS library preparation today and well into the future.
“We are pleased to announce the Juno Targeted DNA Sequencing Library Preparation System as an expansion of our growing portfolio of automated genomic workflows that increase laboratory efficiency for medium-to-high-throughput pipelines,” said Steve McPhail, General Manager of Clinical and Applied Markets at Fluidigm. “We are now able to offer our customers a significant improvement over the largely manual, low-throughput and laborious NGS library preparation workflows used today. Looking forward, we anticipate expanding this offering with a select number of off-the-shelf panels for human health and disease research applications to bring even greater efficiencies to our customers and further advance the progress toward precision medicine.”
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the performance of the Juno Targeted DNA Sequencing Library Preparation System, benefits of such system for customers and the anticipated expansion of the commercial offering. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the potential for delays in the timing of new product releases; the potential for product performance or quality issues in new products and risks associated with Fluidigm’s ability to address such issues; intellectual property risks; competition; Fluidigm’s research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm’s business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, and in its other filings with the Securities and Exchange Commission. Additional information will also be set forth in Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements except as may be required by law.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories and pharmaceutical, biotechnology and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/Fluidigm) and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls and webcasts.
Fluidigm, the Fluidigm logo and Juno are trademarks or registered trademarks of Fluidigm Corporation. All other trademarks are the property of their respective owners.